ClinicalTrials.gg
TerminatedNCT04545385Updated Mar 13, 2023Results posted

A Study to Test if TEV-48574 is Effective in Relieving Asthma

A Phase 2 interventional study of TEV-48574 and Placebo in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Terminated at 97 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Met pre-specified criteria for futility at interim analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. — none open to participants now, 1 under way, 1 of them phase 3. Asthma · Teva Pharmaceutical Industries, Ltd..

Enrollment
38th of 51
65 · median 317
Started
2020
with 1 other
Phase 2
11 of 54
none open now
Registered
49th of 54
by date

Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 38th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 2, and was the 49th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult participants with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).

The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.

The duration of participant participation in the study is planned to be up to approximately 30 weeks.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • T2 low, non-T2 asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of asthma for at least 12 months prior to the initial screening visit.
  • The participant is able to perform technically acceptable and repeatable spirometry, including with a hand-held spirometer, after training
  • The participant has had at least one documented clinical asthma exacerbation in the 18 months prior to (but not within 30 days of) the initial screening visit.
  • The participant is a non-smoker for ≥6 months with lifetime history ≤10 pack-years, with no current ecigarette or marijuana use.

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The participant has any concomitant conditions or treatments that could interfere with study conduct.
  • The participant is currently pregnant or lactating or is planning to become pregnant during the study.
  • The participant has received any live or attenuated vaccine within 15 days of the initial screening visit.

NOTE- Additional criteria apply, please contact the investigator for more information

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    TEV-48574

    Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).

    Drug: TEV-48574

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.

    Drug: Placebo

Interventions

  • subcutaneous infusion

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period

    The LoAC was defined as any 1 of the following during the treatment period: - morning peak expiratory flow (PEF) decrease ≥30% from baseline on 2 consecutive days or morning handheld forced expiratory volume in the first second of exhalation (FEV1) decrease ≥20% from baseline on 2 consecutive days; - increase in short-acting beta-agonist (SABA)/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in inhaled corticosteroids (ICS) dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma emergency room (ER) visit or hospitalization.

    Time frame: From randomization (Week 0) until Week 16

Secondary outcomes

  1. Time From Randomization to LoAC During the Treatment Period

    Time (in days) from randomization to LoAC during the treatment period is the interval from randomization to the occurrence of the LoAC. The LoAC was defined as any 1 of the following during the treatment period: - morning PEF decrease ≥30% from baseline on 2 consecutive days or morning handheld FEV1 decrease ≥20% from baseline on 2 consecutive days; - increase in SABA/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in ICS dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma ER visit or hospitalization.

    Time frame: From randomization (Week 0) until Week 16

  2. Change From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16

    The ACQ-6 is a 6-item validated asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ-6 has a possible score ranges from 0 to 6, and the total score is the mean of all responses. The total score ranging from 0-6 (0=totally controlled and 6=severely uncontrolled). A higher score indicated poorer asthma control.

    Time frame: Baseline, Week 16

  3. Change From Baseline in Percent Predicted Forced Expiratory Volume in the First Second (FEV1) at Week 16

    FEV1 (measured by handheld spirometer) is the volume of air that can be forcibly exhaled from the lungs in the first second. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%.

    Time frame: Baseline, Week 16

  4. Change From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16

    Number of inhalations/puffs of SABA/quick relief inhaler used was recorded in the e-diary daily.

    Time frame: Baseline, Week 16

  5. Number of Participants Who Had a Clinical Asthma Exacerbation (CAE) During the Treatment Period

    The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).

    Time frame: From randomization (Week 0) until Week 16

  6. Time From Randomization to First CAE During the Treatment Period for Participants With CAE

    The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).

    Time frame: From randomization (Week 0) until Week 16

  7. Change From Baseline in Number of Nighttime Awakenings Due to Asthma at Week 16

    Participants recorded the number of nighttime awakenings due to asthma in the e-diary daily, in the morning.

    Time frame: Baseline, Week 16

  8. Percent Change in ICS Dose During the Treatment Period

    The ICS dose was not collected in the participant diary as planned.

    Time frame: From randomization (Week 0) until Week 16

  9. Change From Baseline in Forced Vital Capacity (FVC) at Week 16

    FVC (measured by handheld spirometer) is the volume of air that can be forcibly and completely blown out after full inspiration, measured in liters.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16

    The FEF25%-75% (measured by handheld spirometer) is the forced expiratory flow from 25% to 75% of FVC

    Time frame: Baseline, Week 16

  11. Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 16

    FeNO was performed prior to the on-site spirometry.

    Time frame: Baseline, Week 16

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Serious adverse events (SAEs) included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered treatment emergent (TEAEs) if onset occurred on or after the first dose date. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. AEs include clinically significant changes from baseline in any one of the following categories: clinical laboratory test results, vital signs, ECG findings.

    Time frame: From randomization (Week 0) until Week 24

07

Results

Posted Mar 13, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboTEV-48574
Started3233
Received at least 1 dose of study drug3133
Completed1720
Not completed1513
Withdrew: Withdrawal by subject20
Withdrew: Loss of asthma control (loac)01
Withdrew: Study termination1010
Withdrew: Sponsor decision22
Withdrew: Other than specified10

Outcome measures

PrimaryNumber of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period

The LoAC was defined as any 1 of the following during the treatment period: - morning peak expiratory flow (PEF) decrease ≥30% from baseline on 2 consecutive days or morning handheld forced expiratory volume in the first second of exhalation (FEV1) decrease ≥20% from baseline on 2 consecutive days; - increase in short-acting beta-agonist (SABA)/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in inhaled corticosteroids (ICS) dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma emergency room (ER) visit or hospitalization.

Time frame:
From randomization (Week 0) until Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period
ParticipantsPlaceboTEV-48574
Number of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period1317
Statistical analysis
  • Placebo vs TEV-48574 · Regression, Logistic · p = 0.7817 · Odds ratio (or): 1.49 · 95% CI 0.545 to 4.071
SecondaryTime From Randomization to LoAC During the Treatment Period

Time (in days) from randomization to LoAC during the treatment period is the interval from randomization to the occurrence of the LoAC. The LoAC was defined as any 1 of the following during the treatment period: - morning PEF decrease ≥30% from baseline on 2 consecutive days or morning handheld FEV1 decrease ≥20% from baseline on 2 consecutive days; - increase in SABA/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in ICS dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma ER visit or hospitalization.

Time frame:
From randomization (Week 0) until Week 16
Reported as:
Median · days
Time From Randomization to LoAC During the Treatment Period
daysPlaceboTEV-48574
Time From Randomization to LoAC During the Treatment PeriodNA (60.0 to NA)109.0 (45.0 to NA)
SecondaryChange From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16

The ACQ-6 is a 6-item validated asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ-6 has a possible score ranges from 0 to 6, and the total score is the mean of all responses. The total score ranging from 0-6 (0=totally controlled and 6=severely uncontrolled). A higher score indicated poorer asthma control.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16
units on a scalePlaceboTEV-48574
Change From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16-0.560 ± 0.4546-0.833 ± 0.7250
SecondaryChange From Baseline in Percent Predicted Forced Expiratory Volume in the First Second (FEV1) at Week 16

FEV1 (measured by handheld spirometer) is the volume of air that can be forcibly exhaled from the lungs in the first second. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%.

Time frame:
Baseline, Week 16
Reported as:
Mean · %predicted FEV1
Change From Baseline in Percent Predicted Forced Expiratory Volume in the First Second (FEV1) at Week 16
%predicted FEV1PlaceboTEV-48574
Change From Baseline in Percent Predicted Forced Expiratory Volume in the First Second (FEV1) at Week 160.121 ± 8.31264.844 ± 12.4343
SecondaryChange From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16

Number of inhalations/puffs of SABA/quick relief inhaler used was recorded in the e-diary daily.

Time frame:
Baseline, Week 16
Reported as:
Mean · puffs of SABA/day
Change From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16
puffs of SABA/dayPlaceboTEV-48574
Change From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16-0.235 ± 1.2641-0.305 ± 1.6501
SecondaryNumber of Participants Who Had a Clinical Asthma Exacerbation (CAE) During the Treatment Period

The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).

Time frame:
From randomization (Week 0) until Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Had a Clinical Asthma Exacerbation (CAE) During the Treatment Period
ParticipantsPlaceboTEV-48574
Number of Participants Who Had a Clinical Asthma Exacerbation (CAE) During the Treatment Period23
SecondaryTime From Randomization to First CAE During the Treatment Period for Participants With CAE

The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).

Time frame:
From randomization (Week 0) until Week 16
Reported as:
Median · days
Time From Randomization to First CAE During the Treatment Period for Participants With CAE
daysPlaceboTEV-48574
Time From Randomization to First CAE During the Treatment Period for Participants With CAE46.5 (38 to 55)37.0 (30 to 54)
SecondaryChange From Baseline in Number of Nighttime Awakenings Due to Asthma at Week 16

Participants recorded the number of nighttime awakenings due to asthma in the e-diary daily, in the morning.

Time frame:
Baseline, Week 16
Reported as:
Mean · nighttime awakenings
Change From Baseline in Number of Nighttime Awakenings Due to Asthma at Week 16
nighttime awakeningsPlaceboTEV-48574
Change From Baseline in Number of Nighttime Awakenings Due to Asthma at Week 16-1.224 ± 2.0182-0.208 ± 2.7274
SecondaryPercent Change in ICS Dose During the Treatment Period

The ICS dose was not collected in the participant diary as planned.

Time frame:
From randomization (Week 0) until Week 16

No measurements were reported for this outcome.

SecondaryChange From Baseline in Forced Vital Capacity (FVC) at Week 16

FVC (measured by handheld spirometer) is the volume of air that can be forcibly and completely blown out after full inspiration, measured in liters.

Time frame:
Baseline, Week 16
Reported as:
Mean · liters
Change From Baseline in Forced Vital Capacity (FVC) at Week 16
litersPlaceboTEV-48574
Change From Baseline in Forced Vital Capacity (FVC) at Week 160.014 ± 0.30520.155 ± 0.3964
SecondaryChange From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16

The FEF25%-75% (measured by handheld spirometer) is the forced expiratory flow from 25% to 75% of FVC

Time frame:
Baseline, Week 16
Reported as:
Mean · liters/second
Change From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16
liters/secondPlaceboTEV-48574
Change From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16-0.026 ± 0.24510.166 ± 0.4342
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 16

FeNO was performed prior to the on-site spirometry.

Time frame:
Baseline, Week 16
Reported as:
Mean · parts per billion (ppb)
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 16
parts per billion (ppb)PlaceboTEV-48574
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 165.364 ± 6.960910.375 ± 12.5850
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Serious adverse events (SAEs) included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered treatment emergent (TEAEs) if onset occurred on or after the first dose date. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. AEs include clinically significant changes from baseline in any one of the following categories: clinical laboratory test results, vital signs, ECG findings.

Time frame:
From randomization (Week 0) until Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboTEV-48574
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)1418

Adverse events

Collected over From randomization (Week 0) until Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/31 (0%)1/31 (3.2%)4/31 (12.9%)
TEV-485740/33 (0%)1/33 (3%)6/33 (18.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboTEV-48574
Vaginal prolapseReproductive system and breast disorders1/310/33
Hypertensive crisisVascular disorders0/311/33
Most frequent other events
Most frequent other events
EventPlaceboTEV-48574
NasopharyngitisInfections and infestations3/313/33
HeadacheNervous system disorders2/313/33

Baseline characteristics

The intent-to-treat (ITT) analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboTEV-48574Total
Mean56.3 ± 14.1458.8 ± 12.3857.6 ± 13.23
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTEV-48574Total
Female192241
Male131124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTEV-48574Total
Hispanic or Latino5611
Not Hispanic or Latino272754
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTEV-48574Total
Race — White282654
Race — Black or African American4610
Race — Other011
08

Study locations

97 sites
  • Teva Investigational Site 14884
    Birmingham, Alabama 35209, United States
  • Teva Investigational Site 14915
    Little Rock, Arkansas 72205, United States
  • Teva Investigational Site 14914
    Bakersfield, California 93301, United States
  • Teva Investigational Site 15234
    Huntington Beach, California 92647, United States
  • Teva Investigational Site 14896
    Los Angeles, California 90025, United States
  • Teva Investigational Site 14918
    Los Angeles, California 90025, United States
  • Teva Investigational Site 14913
    Los Angeles, California 90048, United States
  • Teva Investigational Site 14910
    Rolling Hills Estates, California 90274-7604, United States
  • Teva Investigational Site 14907
    San Diego, California 92123, United States
  • Teva Investigational Site 14891
    San Jose, California 95117, United States
  • Teva Investigational Site 15231
    Stockton, California 95207, United States
  • Teva Investigational Site 14916
    Walnut Creek, California 94598, United States
  • Teva Investigational Site 14878
    Westminster, California 92683, United States
  • Teva Investigational Site 14895
    Colorado Springs, Colorado 80907, United States
  • Teva Investigational Site 14917
    Denver, Colorado 80246, United States
  • Teva Investigational Site 15222
    Coral Gables, Florida 33134, United States
  • Teva Investigational Site 15223
    Cutler Bay, Florida 33189, United States
  • Teva Investigational Site 14911
    Hialeah, Florida 33012, United States
  • Teva Investigational Site 15225
    Hialeah, Florida 33015, United States
  • Teva Investigational Site 14900
    Miami, Florida 33134, United States
  • Teva Investigational Site 14883
    Miami, Florida 33173, United States
  • Teva Investigational Site 14908
    Panama City, Florida 32405, United States
  • Teva Investigational Site 14894
    Tallahassee, Florida 32308-4355, United States
  • Teva Investigational Site 15224
    Tampa, Florida 33607, United States
  • Teva Investigational Site 14924
    Evansville, Indiana 47713, United States
  • Teva Investigational Site 14897
    Kansas City, Kansas 66160, United States
  • Teva Investigational Site 15220
    Baltimore, Maryland 21236, United States
  • Teva Investigational Site 14877
    North Dartmouth, Massachusetts 02747-3322, United States
  • Teva Investigational Site 14922
    Saint Louis, Missouri 63110, United States
  • Teva Investigational Site 14893
    Saint Louis, Missouri 63141, United States
  • Teva Investigational Site 14904
    Missoula, Montana 59808, United States
  • Teva Investigational Site 14912
    Bellevue, Nebraska 68123-4303, United States
  • Teva Investigational Site 14903
    Lincoln, Nebraska 68505-2343, United States
  • Teva Investigational Site 15227
    Skillman, New Jersey 08558, United States
  • Teva Investigational Site 15221
    Charlotte, North Carolina 28277, United States
  • Teva Investigational Site 15226
    Monroe, North Carolina 28112, United States
  • Teva Investigational Site 14882
    Raleigh, North Carolina 27607, United States
  • Teva Investigational Site 14887
    Wilmington, North Carolina 28401, United States
  • Teva Investigational Site 14889
    Cincinnati, Ohio 45231, United States
  • Teva Investigational Site 14886
    Dublin, Ohio 43016, United States
  • Teva Investigational Site 14901
    Toledo, Ohio 43617, United States
  • Teva Investigational Site 14888
    Edmond, Oklahoma 73034, United States
  • Teva Investigational Site 14880
    Oklahoma City, Oklahoma 73112-4432, United States
  • Teva Investigational Site 14923
    Philadelphia, Pennsylvania 19140, United States
  • Teva Investigational Site 14890
    Charleston, South Carolina 29406, United States
  • Teva Investigational Site 14925
    Allen, Texas 75013, United States
  • Teva Investigational Site 15230
    Austin, Texas 78759, United States
  • Teva Investigational Site 14909
    Dallas, Texas 75231, United States
  • Teva Investigational Site 14902
    El Paso, Texas 79903-3508, United States
  • Teva Investigational Site 14919
    Fort Worth, Texas 76244, United States
  • Teva Investigational Site 14921
    Houston, Texas 77030, United States
  • Teva Investigational Site 14905
    McKinney, Texas 75069, United States
  • Teva Investigational Site 14879
    San Antonio, Texas 78229, United States
  • Teva Investigational Site 14920
    Spokane, Washington 99204, United States
  • Teva Investigational Site 14881
    Greenfield, Wisconsin 53228, United States
  • Teva Investigational Site 59159
    Kozloduy, 999999, Bulgaria
  • Teva Investigational Site 59166
    Montana, 3400, Bulgaria
  • Teva Investigational Site 59163
    Plovdiv, 4002, Bulgaria
  • Teva Investigational Site 59189
    Plovdiv, 4003, Bulgaria
  • Teva Investigational Site 59190
    Plovdiv, 4003, Bulgaria
  • Teva Investigational Site 59164
    Ruse, 7002, Bulgaria
  • Teva Investigational Site 59168
    Sofia, 1000, Bulgaria
  • Teva Investigational Site 59167
    Sofia, 1606, Bulgaria
  • Teva Investigational Site 59160
    Stara Zagora, 6001, Bulgaria
  • Teva Investigational Site 59161
    Stara Zagora, 999999, Bulgaria
  • Teva Investigational Site 59165
    Varna, 9020, Bulgaria
  • Teva Investigational Site 59162
    Veliko Tarnovo, 5000, Bulgaria
  • Teva Investigational Site 59192
    Vratsa, 3001, Bulgaria
  • Teva Investigational Site 54197
    Brandys nad Labem, 25001, Czechia
  • Teva Investigational Site 54194
    Jindrichuv Hradec, 999999, Czechia
  • Teva Investigational Site 54193
    Miroslav, 671 721, Czechia
  • Teva Investigational Site 54195
    Prague 8, 182 00, Czechia
  • Teva Investigational Site 54203
    Strakonice, 999999, Czechia
  • Teva Investigational Site 54196
    Teplice, 415 01, Czechia
  • Teva Investigational Site 32747
    Berlin, 10787, Germany
  • Teva Investigational Site 32741
    Frankfurt am Main, 60596, Germany
  • Teva Investigational Site 32759
    Frankfurt/Main, 60389, Germany
  • Teva Investigational Site 32744
    Geesthacht, 21502, Germany
  • Teva Investigational Site 32739
    Hamburg, 22299, Germany
  • Teva Investigational Site 32746
    Hannover, 30173, Germany
  • Teva Investigational Site 32757
    Leipzig, 04537, Germany
  • Teva Investigational Site 32758
    Leipzig, 4157, Germany
  • Teva Investigational Site 32756
    Leipzig, ?04275, Germany
  • Teva Investigational Site 32742
    Luebeck, 23552, Germany
  • Teva Investigational Site 32743
    Muenchen, 81241, Germany
  • Teva Investigational Site 32745
    Rheine, 48431, Germany
  • Teva Investigational Site 53461
    Bydgoszcz, 85-231, Poland
  • Teva Investigational Site 53458
    Krakaw, 31-033, Poland
  • Teva Investigational Site 53457
    Krakow, 31-559, Poland
  • Teva Investigational Site 53455
    Lodz, 90-302, Poland
  • Teva Investigational Site 53483
    Poznan, 60 - 823, Poland
  • Teva Investigational Site 53459
    Poznan, 60-214, Poland
  • Teva Investigational Site 53486
    Sucha Beskidzka, 34200, Poland
  • Teva Investigational Site 53462
    Tarnow, 33-100, Poland
  • Teva Investigational Site 53485
    Warszawa, 01-868, Poland
  • Teva Investigational Site 53460
    Wroclaw, 53-201, Poland
  • Teva Investigational Site 53456
    Wroclaw, 53-301, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jan 2022, 15 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2020
First posted
Sep 11, 2020
StartActual
Oct 7, 2020
Primary completionActual
Jan 17, 2022
CompletionActual
Jan 17, 2022
Results first posted
Mar 13, 2023
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04545385
Responsible party
Sponsor
First posted
Sep 11, 2020
Start date
Oct 7, 2020
Primary completion
Jan 17, 2022
Completion
Jan 17, 2022
Results posted
Mar 13, 2023
Last update
Mar 13, 2023

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvakitug

Start the discussion